Highly rated in
Highly rated in
Check Dr. Michael A. Finan's experience treating your condition:
About Dr. Michael A. Finan

Michael Finan is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Pascagoula, Mississippi. Finan has been practicing medicine for over 37 years and is highly rated in 10 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Testicular Yolk Sac Tumor, Virilizing Ovarian Tumor, Hysterectomy, and Salpingo-Oophorectomy. He is licensed to treat patients in Mississippi and Alabama. Finan is currently accepting new patients.

His clinical research consists of co-authoring 21 peer reviewed articles and participating in 16 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Michael A. Finan it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Michael A. Finan accepts the following insurance:

  •  Ambetter
  •  Molina Healthcare
  •  Cigna
  •  UnitedHealthcare
2809 Denny Ave, Pascagoula, MS 39581
Background & Education
Graduate Institution
Louisiana State University School Of Medicine In Shreveport, 1986
Gynecologic Oncology
Obstetrics and Gynecology
Obstetrics & Gynecology in AL
Hospital Affiliations
Pascagoula Hospital
Singing River Gulfport
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Molecular Analysis for Therapy Choice (MATCH)
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
View 8 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors